, and are modulated by group I GRMs in transgenic mouse melanoma models with GRM1 or GRM5 expression (Choi, Chang, Pickel, Badger, & Roche, 2011; Ohtani et al., 2008; Pollock et al., 2003b) .
Our group previously reported that ectopic expression of GRM1 in melanocytes leads to melanocyte transformation in vitro and tumorigenesis in vivo. In our comprehensive examination of 25 human melanoma cell lines and 175 melanoma biopsies including primary and metastatic lesions, 80% of cell lines and 60% of tumor biopsies express GRM1, while normal melanocytes from the same patients do not express GRM1 (Namkoong et al., 2007b) .
Stimulation of the receptor by glutamate or agonist results in activation of the MAPK and PI3K/AKT pathways (Lee et al., 2011; Namkoong et al., 2007b; Pollock et al., 2003a) . With these results suggesting that GRM1 is a potential target for the treatment of patients with melanoma, the clinically available agent riluzole, an inhibitor of GRM 1 signaling used for the treatment of amyotrophic lateral sclerosis, was selected for further preclinical studies (Miller, 2003; Miller, Mitchell, Lyon, & Moore, 2003; Mitsumoto, 1997; Noh, Hwang, Shin, & Koh, 2000) .
Treatment of human melanoma cell lines and xenografts with riluzole or other GRM1 signal transduction inhibitors results in reduced cell proliferation in vitro and decreased tumor growth in vivo independent of N-RAS/B-RAF genotypes (Le et al., 2010; Lee et al., 2011; Namkoong et al., 2007a; Wangari-Talbot, Wall, Goydos, & Chen, 2012) . Based on these findings, we conducted a 12-patient, pilot phase 0 trial of riluzole in patients with stage III and IV melanoma who were to undergo curative or palliative resection (Yip et al., 2009 ). Approximately one-third of patients treated with 100 mg bid of oral riluzole for 14 days showed metabolic reponses to treatment on PET-CT and evidence of suppression of pERK and pAKT signaling in the corresponding paired tumor samples. Our pilot study results led to the design of this phase II trial to determine the antitumor activity of riluzole in patients with advanced melanoma.
| RE SULTS
Thirteen patients, seven male and six females, were enrolled. The majority of patients had an ECOG performance status of 1. Baseline patient characteristics including the prior treatments are summarized in Table S1 . No patients had prior treatment with inhibitors of B-RAF or MEK, or checkpoint inhibitors.
Treatment delivery and discontinuation results are summarized in Table S2 . Six patients received two 4-week cycles, five received between two and four cycles, and one received >4 cycles of riluzole. One patient completed only one cycle due to early disease progression. The median number of days on therapy was 54. Dose interruptions and reductions were required in two patients due to dizziness. One patient, per protocol, was permitted to receive concomitant radiation to a painful lesion present at baseline and considered not to be indicative of progression. The reasons for treatment discontinuation were disease progression in 12 of 13 patients, and toxicity (grade 3 dizziness) in 1 of 13 patients.
Adverse events noted in patients treated on this trial are summarized in Table S3 . Overall, riluzole was well tolerated. No grade 4 of 5 toxicities related to therapy were reported. Grade 3 toxicities possibly, probably, or definitely related to treatment included dehydration in one patient (8%) and dizziness in five patients (38%).
Two patients with dizziness required dose reduction for the management of symptoms. One of these patients required discontinuation of protocol therapy due to persistent dizziness even with multiple dose reductions. The second patient was dose reduced to 100 mg daily and subsequently re-escalated successfully after resolution of symptoms. One patient died due to progressive disease within the first cycle; no other deaths were reported on trial or within 30 days of the last dose of riluzole.
No objective responses per RECIST criteria were observed. At the first restaging scan scheduled after 6 weeks of therapy, six of 13 patients (46%) showed stable disease as the best response. The response results along with data of correlative studies are summarized in Table 1 The median overall survival (OS) observed was 342 days (95% CI = 148-720 days). Figure S1 shows the Kaplan-Meier plots of PFS
Significance
The findings of our phase II trial of riluzole in patients with advanced melanoma have practical implications for future exploration of GRM1 targeting agents. With no RECIST responses and disease stabilization as the best outcome, further study of single-agent riluzole was not recommended.
Suppression of GRM1-related signaling pathways and increased leukocyte infiltration, potential indicators of biologic activity, was noted in tumor specimens from a subset of treated patients. Moving forward, studying agents with improved bioavailability, and studying the effects on the immune microenvironment, including combinatorial studies with immune modulating agents, may yield important insights.
and OS, indicating a 6-month PFS rate of 15.38% (95% CI = 2.5%-38.8%) and the 1-year OS rate of 46.15% (95% CI = 19.2%-69.6%).
Steady-state plasma riluzole trough levels ranged from 8.16 to 294.4 ng/ml. Table S4 shows the plasma riluzole trough levels on day 8 and day 10. There was a large interpatient variation in trough plasma concentrations, and the mean trough levels of riluzole were 86.99 ± 80.04 ng/ml (day 8) and 119.08 ± 108.03 ng/ml (day 10).
The interindividual variability in plasma riluzole levels in melanoma patients was similar to that of patients with ALS Groeneveld et al., 2001 ).
The varied trough levels between patients are likely attributable to differences in absorption and metabolism of riluzole.
All 13 tumors (100%) at baseline were positive for GRM1 expression by IHC staining, similar to results seen in our prior phase 0 trial (Yip et al., 2009) . As expected, GRM1 staining was localized to the membrane on melanoma tumor cells ( Figure S2 ). In light of our preclinical observations that GRM-overexpressing xenograft tumors are larger and demonstrate higher microvessel density, and that higher levels of VEGF and IL-8 have been observed in conditioned medium from melanoma cells which overexpress GRM1, we hypothesized that GRM1 functions to promote angiogenesis in melanoma, with antagonism of GRM1 resulting in decreased angiogenesis (Koochekpour et al., 2012; Lee, Wall, Wangari-Talbot, & Chen, 2012) . To investigate this further in human samples, we performed Western blot analysis for the endothelial marker CD31 to evaluate the degree of angiogenesis in pre-and post-treatment tumor samples. CD31 levels on Western blot decreased in patients 1, 5, and 11 and also decreased in patient 12 (Figure 1a,d ).
Tumors from patients 1, 5, and 11 whose tumors exhibited decreased pERK, pAKT, and CD31 on Western blot were selected for IHC analyses. Staining was performed for pERK and CD31, as well as for cleaved caspase-3 for evidence of increased apoptosis, which was seen in the prior phase 0 trial (Yip et al., 2009) Imaging for tumor assessments was performed after 6 weeks. The response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST; Therasse et al., 2000) . Tumor samples were obtained before and after treatment from 8 of the 13 enrolled patients. The procedures to determine B-RAF and N-RAS genotypes were detailed earlier (Yip et al., 2009 ).
To analyze the effects of riluzole on immune cells in the tumor microenvironment, four paired tumor samples with adequate remaining tissue (patients #1, 6, 8, and 11) were examined for leukocytes (identified using CD45) and macrophages (identified using CD68).
Quantitative analysis of the data for CD45+ and CD68+ cells inside the tumor, at the tumor-stromal interface, and in the stroma in these patients is shown in Figure 3a ,b. In two patients with stable disease (patient #1 and #11), CD45+ leukocytes at the tumor-stromal interface were increased in the post-treatment tumor samples (Figure 3a,c) .
In two patients with progressive disease (patient #6 and #8), intratumoral leukocytes were decreased in the post-treatment tumor sample (Figure 3a) . Cells staining positive for CD68+ macrophages at the F I G U R E 1 Western blots showing signaling response in paired tumor samples for ERK, pERK, pAKT308, total AKT, and CD31. Tumor tissue protein lysates were prepared as described (Yip et al., 2009) , and 10 μg of total protein lysate was resolved on 4%-20% SDS-PAGE gels. Resolved proteins were blotted to polyvinylidene difluoride membranes by standard procedures and probed with antibodies as indicated in the figure legends. Probed and chemiluminated protein bands were exposed and captured by a Syngene G: Box Chemiluminescence imaging system with the auto-exposure mode, which is determined by the strongest band intensity on each blot. The band intensity quantities were obtained by the supporting software Gene Tools from SynGene. tumor-stromal interface were also increased in two samples (one coincident with an increase in CD45+), decreased in one sample, and remained the same in one sample (Figure 3b ).
N-RAS and B-RAF mutation status determination showed that
tumors from patients 1, 2, 3, 4, and 9 carried B-RAF V600E mutations, and patient 10 was found to have a mutation in N-RAS (Table 1) . Within this small sample size, downregulation of pERK and pAKT occurred on treatment irrespective of tumor mutation status.
| D ISCUSS I ON
This trial was designed with the primary objective of response rate, an appropriate endpoint given our hypothesis that clinically relevant tumor shrinkage would be achieved based on our preclinical and phase 0 data (Le et al., 2010; Namkoong et al., 2007a; Yip et al., 2009 ). However, the best response observed was stable disease, noted in 46% of patients at first restaging. With no responses observed per RECIST criteria, the trial was terminated. While nearly half of the patients showed stable disease at first restaging, the duration of disease stabilization was, overall, relatively short and, as such, is of limited clinical significance (Vidaurre, Wilkerson, Simon, Bates, & Fojo, 2009 ), although prolonged disease stabilization was seen in a previous patient whose tumor, with N-Ras mutation status, had been previously progressing.
A dose-escalation phase I trial was not performed given the evidence of biologic activity in our phase 0 trial at 100 mg bid. This is the maximum dose utilized in clinical practice with most ALS patients treated with a schedule of 50 mg bid. We chose the 100 mg bid dose based on the assumption that a higher degree of toxicity may be acceptable in cancer patients with the immediate life-threatening disease when compared to patients with the more chronic illness.
At this higher dose level tested in our phase II study, riluzole was, overall, well tolerated.
The potency and bioavailability of riluzole present challenges to its clinical use (Jablonski et al., 2014) . Results of our pharmacokinetic analysis indicate that absorption of riluzole among subjects exhibited variability, consistent with studies of riluzole in ALS subjects (Groeneveld et al., 2001 ). While our sample size is too small to draw definitive conclusions, higher serum levels of riluzole did not correlate with biologic activity in tumor tissue or disease control, a phenomenon also observed in studies of riluzole in patients with ALS . One hypothesis to explain this effect is the possibility that N-hydroxyriluzole, produced after riluzole is metabolized in the liver by cytochrome p450 and not measured in our analysis or previous analyses, exists as a pharmacologically active metabolite . Alternatively, riluzole could be eliminated through glucuronidation or extrahepatic CYP1A1 activity . The steady-state concentration of riluzole in our study was highly variable, consistent with prior reports, and may be due to a variable first pass effects from heterogeneous CYP1A2 expression (Mcdonnell et al., 2012) . Efforts are underway to design more promising prodrugs that remain stable while transiting the digestive system and through first pass metabolism, becoming metabolically labile in the plasma and releasing riluzole (Mcdonnell et al., 2012) .
The findings of this study are consistent with observations from our earlier phase 0 trial, which indicated biologic activity on PET scans and in tumor tissue in one-third of study subjects after 2 weeks of riluzole. Indeed, three of eight patients with biopsiable tissue treated on the phase 2 trial showed evidence of disease stabilization on CT scans and decreased pERK and pAKT, indicating suppressed MAPK and PI3K signaling. This biochemical suppression of active pathways is expected as it is known that activation of GRM1 leads to a dual signaling cascade that stimulates both MAPK and PI3K pathways which could be inhibited by riluzole Lee et al., 2012; Marin et al., 2006) . 
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